1st Quarter 2021
Key topics in this quarter’s edition include:
- Abrocitinib, tralokinumab, and topical ruxolitinib for the treatment of atopic dermatitis
- Pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria
- Relugolix/estradiol/norethindrone acetate for the treatment of uterine fibroids
Top